A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
Phase of Trial: Phase III
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Evolocumab (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Amgen
- 31 Jul 2017 Planned End Date changed from 21 Sep 2022 to 22 Oct 2022.
- 31 Jul 2017 Planned primary completion date changed from 21 Sep 2022 to 22 Oct 2022.
- 22 Mar 2017 Status changed from not yet recruiting to recruiting.